
Opinion|Videos|March 14, 2025
Treatment Insights From RESPONSE: Ruxolitinib Therapy in Hydroxyurea-Resistant/Intolerant Disease
Author(s)Daniel Landau, MD
An expert discusses how the positive efficacy findings from the phase 3 RESPONSE trial, showing high rates of hematocrit control and spleen response with ruxolitinib vs standard therapy in hydroxyurea-resistant/intolerant polycythemia vera (PV), have enhanced the treatment approach for patients with inadequate response to hydroxyurea.
Advertisement
Episodes in this series

Video content above is prompted by the following:
The phase 3 RESPONSE trial findings showed high rates of hematocrit control and spleen response with ruxolitinib vs standard therapy in hydroxyurea-resistant/intolerant PV (
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts NDA for Daraxonrasib in Metastatic Pancreatic Cancer
2
FDA Approves Zidesamtinib for Previously Treated ROS1-Positive NSCLC
3
Advanced Renal Cell Carcinoma: Tailoring Second-Line Therapy After Prior Immunotherapy
4
Optimizing Second-Line Therapy in Metastatic ccRCC
5























